Pharmaceutical Technology

AUGUST 1, 2022

GreenLight Biosciences has entered a partnership with the US National Institutes of Health (NIH) for the development of Covid-19 vaccines, which offer broader protection against new variants and with durable effects. They intend to develop vaccines that provide lasting immune responses compared to existing vaccines.

Vaccination 245

Vaccination Vaccine Development RNA 245

Pharmaceutical Technology

MAY 19, 2023

ImmunoForge has expanded its licence agreement with Duke University in North Carolina, US, to jointly improve research and drug development opportunities. ImmunoForge chief technology officer Dr Jim Balance pioneered the clinical development of peptide drugs genetically fused to ELPs.

Development 130

Development Drugs Licensing Licensing 130

Drug Discovery World

FEBRUARY 28, 2024

Lu Rahman selects some of the year’s interesting and noteworthy advances in cancer research drug discovery and development. As always, a year within cancer drug discovery and development brings with it significant breakthroughs, and 2023 has been no exception. Research into new cancer drugs remain strong.

Development 64

Development Research Drugs Antibody 64

Pharmaceutical Technology

MARCH 24, 2023

Moderna has entered a strategic partnership with Generation Bio for the development of non-viral genetic medicines. The collaboration aims to expand each company’s platform application through the development of new nucleic acid therapeutics, and to expedite their respective non-viral genetic medicines pipelines.

Genetics 130

Genetics Medicine Development In-Vivo 130

Pharmaceutical Technology

JANUARY 5, 2023

Capsida Biotherapeutics and Eli Lilly and Company ’s wholly owned subsidiary Prevail Therapeutics have announced a partnership for the development of non-invasive gene therapies for central nervous system (CNS) diseases. The post Capsida Biotherapeutics and Prevail to develop CNS gene therapies appeared first on Pharmaceutical Technology.

Gene Therapy 237

Gene Therapy Gene Development Engineer 237

Pharmaceutical Technology

OCTOBER 4, 2022

Developed under joint research between Shionogi and Hokkaido University, the antiviral averts SARS-CoV-2 replication by hindering 3CL protease. The post Shionogi and MPP enter Covid-19 antiviral licensing deal appeared first on Pharmaceutical Technology.

Licensing 147

Licensing Licensing Manufacturing Medicine 147

Pharmaceutical Technology

FEBRUARY 9, 2023

ReviR Therapeutics has signed a research collaboration and option-to-license agreement with Asieris Pharmaceuticals to discover new oncology therapeutics. Its initial focus is to develop therapeutics in oncology, CNS, and genetically defined disease indications.

Development 241

Development RNA Gene Therapy Genetics 241

Pharmaceutical Technology

AUGUST 2, 2022

Sosei Heptares , a corporate brand of Sosei Group Corporation, has signed a new drug discovery partnership and option-to-license agreement with AbbVie for discovering, developing and marketing new therapies for neurological ailments. On signing of the deal, AbbVie will make an upfront payment of $40m to Sosei Heptares.

Development 147

Development Licensing Licensing Branding 147

Pharmaceutical Technology

APRIL 26, 2023

MiNA Therapeutics has entered into a research collaboration and option licensing agreement with BioMarin Pharmaceutical to speed up the development of therapeutic ribonucleic acid activation (RNAa) candidates to treat rare genetic diseases. The option licensing agreement is based on early-stage clinical results.

Development 130

Development Genetic Disease Genetics Gene Therapy 130

Bio Pharma Dive

JANUARY 6, 2023

The drugmaker said it is considering licensing out some assets to shorten development timelines, and will stop work on early viral-based gene therapies.

Gene Therapy 152

Gene Therapy Licensing Licensing Gene 152

Pharmaceutical Technology

DECEMBER 6, 2022

Evaxion Biotech and ExpreS 2 ion Biotechnologies have entered a vaccine discovery collaboration agreement to co-develop a new cytomegalovirus (CMV) vaccine candidate. Additionally, this project will be part of the development pipeline of Evaxion under EVX-V1.

Vaccination 130

Vaccination Vaccine Development Immune Response 130

Pharmaceutical Technology

MAY 9, 2023

Biotechnology company Neuro3 Therapeutics has signed an exclusive worldwide licence and option agreement with pharmaceutical firm Lundbeck to develop and commercialise clinical stage KCNQ2 activators. The company will also handle the further development of these programmes through clinical proof-of-concept (PoC).

Development 130

Development Licensing Licensing Research 130

Outsourcing Pharma

MARCH 2, 2023

A licensing agreement has been signed that will give Spanish pharma company, Ferrer, worldwide rights to a treatment for progressive supranuclear palsy (PSP).

Licensing 52

Licensing Licensing Pharma Companies Development 52

Pharmaceutical Technology

APRIL 17, 2023

Telix has announced the successful preclinical development of radiolabelled olaratumab, an antibody licensed by Eli Lilly and Company. Olaratumab will be denoted as TLX300 in Telix’s development pipeline. Telix has demonstrated proof-of-concept (PoC) and will now progress to first-in-human clinical studies.

Development 130

Development Antibody Pharma Companies Licensing 130

BioTech 365

AUGUST 1, 2021

GC Pharma and Tottori University Enter Research Collaboration and License Agreement for Development of GM1 Gangliosidosis Chaperone Therapy GC Pharma and Tottori University Enter Research Collaboration and License Agreement for Development of GM1 Gangliosidosis Chaperone Therapy – Collaboration aims to … Continue reading →

Licensing 40

Licensing Licensing Development Research 40

Drug Discovery World

JULY 21, 2023

Cancer Research Horizons has signed a collaboration agreement to license the entire Twist Biopharma Solutions Library of Libraries. The post Partnership could enhance antibody discovery for cancer research appeared first on Drug Discovery World (DDW).

Antibody 98

Antibody Research Licensing Licensing 98

Pharmaceutical Technology

AUGUST 4, 2022

Poseida Therapeutics and Roche have signed a strategic partnership and licence agreement to develop allogeneic CAR-T cell therapies for hematologic malignancies. Roche and Poseida will also partner in a research programme for creating and developing next-generation features and enhancements for allogeneic CAR-T therapies.

Development 147

Development Clinical Trials Clinical Trials Gene Therapy 147

Pharmaceutical Technology

DECEMBER 14, 2022

Merck and Synplogen have signed a non-binding Memorandum of Understanding (MoU) to expedite the development and manufacturing of viral vector-based gene therapy applications. The firms intend to merge their expertise to provide simplified viral vector gene therapy development, production and testing in Japan.

Gene Therapy 130

Gene Therapy Gene Development Manufacturing 130

BioTech 365

NOVEMBER 10, 2021

Secarna Pharmaceuticals and Achilles Therapeutics sign research, option and license agreement to develop optimized T … Continue reading → KG / Key word(s): Agreement 10.11.2021 / 14:00 The issuer is solely responsible for the content of this announcement.

Licensing 40

Licensing Licensing Development Research 40

Pharmaceutical Technology

NOVEMBER 18, 2022

Regeneron Pharmaceuticals has entered a collaboration and licensing agreement with CytomX Therapeutics for developing conditionally-activated bispecific cancer therapies. This collaboration will use Regeneron’s Veloci-Bi bispecific antibody development platform and CytomX's Probody therapeutic platform.

Development 130

Development Antibody Licensing Licensing 130

BioSpace

OCTOBER 21, 2021

The license and collaboration agreement allows Janssen to use F-star’s proprietary technology in the research, development and commercialization of novel bispecific antibodies.

Licensing 82

Licensing Licensing Antibody Development 82

BioPharma Reporter

AUGUST 1, 2023

Renaissance Pharma, a company focused on the development of life changing therapies in pediatric rare disease, has entered into an exclusive license agreement with St. Jude Childrenâs Research Hospital for Hu14.18, a humanised antibody in development by the hospital for the treatment of newly diagnosed high-risk neuroblastoma.

Research 87

Research Licensing Licensing Antibody 87

Pharmaceutical Technology

AUGUST 16, 2022

Q32 Bio has signed a partnership and option agreement with Horizon Therapeutics for developing ADX-914 to treat autoimmune ailments. According to the deal, Horizon will provide the funding to develop the therapy until the conclusion of its two Phase II clinical trials.

Development 130

Development Clinical Trials Clinical Trials FDA Approval 130

BioTech 365

DECEMBER 7, 2020

Aligos Enters into an Exclusive License and Research Collaboration Agreement with Merck to Discover and Develop an Oligonucleotide Therapy for NASH Aligos Enters into an Exclusive License and Research Collaboration Agreement with Merck to Discover and Develop an Oligonucleotide Therapy … Continue reading →

Licensing 40

Licensing Licensing Development Research 40

BioTech 365

FEBRUARY 18, 2021

Announces License and Research Agreement with Philips ClearPoint Neuro, Inc. Announces License and Research Agreement with Philips Collaboration will Enable ClearPoint to Develop and Launch the ClearPoint ‘Maestro™’ Brain Model by 2022 IRVINE, Calif., ClearPoint Neuro, Inc.

Licensing 40

Licensing Licensing Research Development 40

BioTech 365

MAY 4, 2021

Ablexis Announces Multi-Target License Agreement with Tanabe Research Laboratories U.S.A. Ablexis Announces Multi-Target License Agreement with Tanabe Research Laboratories U.S.A.

Licensing 52

Licensing Licensing Research Antibody 52

Scienmag

MARCH 7, 2021

Bill & Melinda Gates Medical Research Institute to develop formulation -AGREEMENT ADVANCES EVOLUTION OF SYNTHETIC LUNG SURFACTANTS TO TREAT RESPIRATORY DISTRESS SYNDROME IN PREMATURE INFANTS IN LOW- AND MIDDLE-INCOME COUNTRIES- LOS ANGELES (March 8, 2021) — The Lundquist Institute (TLI) and The Bill & Melinda Gates Medical Research (..)

Licensing 40

Licensing Licensing Development Research 40

Pharmaceutical Technology

AUGUST 24, 2022

Lacerta Therapeutics has entered a new licensing and research partnership agreement with Eli Lilly and Company subsidiary, Prevail Therapeutics, to discover and develop adeno-associated virus (AAV) capsids for treating central nervous system (CNS) diseases. .

Development 130

Development Gene Therapy Genetics Gene 130

BioPharma Reporter

JULY 25, 2023

ImmunoGen, a biotech company focused on the development of antibody-drug conjugate (ADC) technology to treat cancer, has announced a multi-target license and option agreement to research novel, first-in-class ADCs with ImmunoBiochem, a biopharma firm developing novel biological therapeutics.

Development 52

Development Licensing Licensing Antibody 52

BioPharma Reporter

FEBRUARY 12, 2021

AbbVie and Caribou Biosciences have entered into a collaboration and license agreement for the research and development of chimeric antigen receptor (CAR)-T cell therapeutics.

Development 98

Development Licensing Licensing Research 98

BioTech 365

APRIL 13, 2021

RubrYc Therapeutics Announces a Research Collaboration and License Option Agreement With Zai Labs RubrYc Therapeutics Announces a Research Collaboration and License Option Agreement With Zai Labs SAN CARLOS, Calif.–(BUSINESS –(BUSINESS WIRE)–RubrYc Therapeutics, Inc.,

Licensing 52

Licensing Licensing Research Development 52

Camargo

DECEMBER 13, 2021

The development of biological products (or biologics) represents a major advancement in modern medicine, enabling the treatment of patients with many illnesses where no other therapeutics were previously available. Regulatory Considerations for Biologics. BLA process (CBER). 510(k) process (CBER). Premarket Approval (PMA) process (CBER).

Development 161

Development Production Immune Response Licensing 161

BioPharma Reporter

DECEMBER 6, 2021

Australiaâs Noxopharm has in-licensed novel RNA tech developed by Hudson Institute of Medical Research: focusing on RNA drug discovery and mRNA vaccine manufacture via Noxopharmâs subsidiary Pharmorage.

RNA 52

RNA Licensing Licensing Vaccination 52

The Pharma Data

JUNE 2, 2022

Boehringer Ingelheim and the Agency for Science, Technology and Research (A*STAR) today announced a global licensing agreement under which Boehringer Ingelheim will obtain exclusive worldwide rights to research, develop and commercialize products based on a panel of innovative, tumor-specific antibodies from A*STAR.

Antibody 52

Antibody Licensing Licensing Development 52

Drug Discovery World

JANUARY 5, 2024

AbbVie and Umoja Biopharma have entered into two exclusive option and license agreements to develop multiple in-situ generated CAR-T cell therapy candidates in oncology. The first agreement provides AbbVie an exclusive option to license Umoja’s CD19 directed in-situ generated CAR-T cell therapy candidates.

In-Vivo 52

In-Vivo Development Licensing Licensing 52

Pharmaceutical Technology

DECEMBER 19, 2022

With the latest development, Sanofi will licence a NK cell engager programme that acts on B7H3 from the antibody-based NK cell engager therapeutics (ANKET) platform of Innate. On choosing the candidate, the company will oversee the complete development, production and marketing.

Development 264

Development Engineer Licensing Licensing 264

Drug Discovery World

NOVEMBER 6, 2023

Cancer Research UK and the KWF Dutch Cancer Society (KWF) have announced a new multi-project strategic partnership to advance promising therapeutic agents for cancer. Both parties will have the opportunity to identify and nominate potential projects for clinical development. The CDD will sponsor and manage KWF-supported trials.

Research 52

Research Clinical Trials Clinical Trials Clinical Development 52